OBJECTIVES: Despite the growing number of elderly patientswith lung cancers,we lack adequate information about how best to treat them. A phase III trial demonstrated a survival benefit of doublet chemotherapy in elderly patients with lung cancers compared to single agents at the cost of increased toxicity. We undertook this study to identify and describe chemotherapyassociated toxicity patterns among elderly patients treated for lung cancers. MATERIALS AND METHODS: We reviewed records of patients age 70 or older with metastatic lung cancers who received initial chemotherapy at the Memorial Sloan-Kettering Cancer Center during 2008 and 2009. RESULTS: We identified 70 patients: 28 (40%) completed at least 4 cycles of chemotherapy without dose reduction but 31 (44%) required hospitalization for toxicity. Baseline albumin <3.5 g/dL and anemiawere associatedwith grade 3–5 chemotherapy-associated toxicity. Also, an increase in platelets from cycle 1 to cycle 2 was associated with chemotherapy-associated toxicity. No other statistically significant associations between chemotherapy-associated toxicity and putative biologic and functional risk factors, including age and performance status, were identified. CONCLUSION: Patients deemed eligible for chemotherapy by their physicianswere just as likely to have severe chemotherapy-associated toxicity requiring hospitalization as to finish an initial course of therapy without any serious problems. An increase in platelet count from cycle 1 to cycle 2 was associated with increased toxicity. Additional research, such as exploration of inflammatory cytokines (PDGF, IL6, and IGF-1) to identify the mechanisms of chemotherapy tolerance and prospective evaluation and validation of existing metrics, is needed so that all patients can be appropriately risk stratified.
OBJECTIVES: Despite the growing number of elderly patientswith lung cancers,we lack adequate information about how best to treat them. A phase III trial demonstrated a survival benefit of doublet chemotherapy in elderly patients with lung cancers compared to single agents at the cost of increased toxicity. We undertook this study to identify and describe chemotherapyassociated toxicity patterns among elderly patients treated for lung cancers. MATERIALS AND METHODS: We reviewed records of patients age 70 or older with metastatic lung cancers who received initial chemotherapy at the Memorial Sloan-Kettering Cancer Center during 2008 and 2009. RESULTS: We identified 70 patients: 28 (40%) completed at least 4 cycles of chemotherapy without dose reduction but 31 (44%) required hospitalization for toxicity. Baseline albumin <3.5 g/dL and anemiawere associatedwith grade 3–5 chemotherapy-associated toxicity. Also, an increase in platelets from cycle 1 to cycle 2 was associated with chemotherapy-associated toxicity. No other statistically significant associations between chemotherapy-associated toxicity and putative biologic and functional risk factors, including age and performance status, were identified. CONCLUSION:Patients deemed eligible for chemotherapy by their physicianswere just as likely to have severe chemotherapy-associated toxicity requiring hospitalization as to finish an initial course of therapy without any serious problems. An increase in platelet count from cycle 1 to cycle 2 was associated with increased toxicity. Additional research, such as exploration of inflammatory cytokines (PDGF, IL6, and IGF-1) to identify the mechanisms of chemotherapy tolerance and prospective evaluation and validation of existing metrics, is needed so that all patients can be appropriately risk stratified.
Authors: Luigi Ferrucci; Jack M Guralnik; Chiara Cavazzini; Stefania Bandinelli; Fulvio Lauretani; Benedetta Bartali; Lazzaro Repetto; Dan L Longo Journal: Crit Rev Oncol Hematol Date: 2003-05 Impact factor: 6.312
Authors: Rogerio C Lilenbaum; James E Herndon; Marcy A List; Chris Desch; Dorothy M Watson; Antonius A Miller; Stephen L Graziano; Michael C Perry; Wayne Saville; Philippe Chahinian; Jane C Weeks; Jimmie C Holland; Mark R Green Journal: J Clin Oncol Date: 2005-01-01 Impact factor: 44.544
Authors: Corey J Langer; Judith Manola; Patricia Bernardo; John W Kugler; Philip Bonomi; David Cella; David H Johnson Journal: J Natl Cancer Inst Date: 2002-02-06 Impact factor: 13.506
Authors: D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey Journal: Am J Med Date: 1980-10 Impact factor: 4.965
Authors: Eugenie Younger; Saskia Litière; Axel Le Cesne; Olivier Mir; Hans Gelderblom; Antoine Italiano; Sandrine Marreaud; Robin Lewis Jones; Alessandro Gronchi; Winette T A van der Graaf Journal: Oncologist Date: 2018-04-12
Authors: Alex Z Fu; Huei-Ting Tsai; John L Marshall; Andrew N Freedman; Arnold L Potosky Journal: J Oncol Pharm Pract Date: 2013-10-11 Impact factor: 1.809
Authors: Beatriz Korc-Grodzicki; William Tew; Arti Hurria; Heidi Yulico; Stuart Lichtman; Paul Hamlin; George Bosl Journal: J Oncol Pract Date: 2017-02 Impact factor: 3.840
Authors: Sarah Z Hazell; Nicholas Mai; Wei Fu; Chen Hu; Cole Friedes; Alex Negron; Khinh Ranh Voong; Josephine L Feliciano; Peijin Han; Samantha Myers; Todd R McNutt; Russell K Hales Journal: BMC Cancer Date: 2020-04-19 Impact factor: 4.430